Mepolizumab Reduces Steroid Use in COPD Patients, Analysis Shows
Patients with chronic obstructive pulmonary disease (COPD) require 29% to 36% less systemic corticosteroid therapy when treated with mepolizumab as an add-on to inhaled triple therapy, according to a pooled analysis presented on October 20 at the American College of Chest Physicians annual meeting in Phoenix. Clinical guidelines often rely on systemic corticosteroids to manage … Read more
